Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema

NCT01702441 is registered in ClinicalTrials.gov with Aerpio Therapeutics as lead sponsor.

NCT NCT01702441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01702441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema
Lead sponsor
Aerpio Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2012
Completion date
December 31, 2014
Enrollment
24 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme)